Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.

Hird, V; Maraveyas, A; Snook, D; Dhokia, B; Soutter, W P; Meares, C; Stewart, J S; Mason, P; Lambert, H E; Epenetos, A A

Hird, V; Maraveyas, A; Snook, D; Dhokia, B; Soutter, W P; Meares, C; Stewart, J S; Mason, P; Lambert, H E; Epenetos, A A.

Affiliation

Hird V; Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.

Br J Cancer ; 68(2): 403-6, 1993 Aug.

Article in En | MEDLINE | ID: mdl-8347497

Subject(s)

Ovarian Neoplasms/radiotherapy; Radioimmunotherapy/adverse effects; Actuarial Analysis; Adult; Aged; Antibodies, Monoclonal/therapeutic use; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms/mortality; Ovarian Neoplasms/pathology; Ovarian Neoplasms/therapy; Survival Analysis; Time Factors; Yttrium Radioisotopes/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Radioimmunotherapy Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 1993 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google